GlobeNewswire

Chinese tourists can now use Alipay in all 242 Starbucks across Malaysia

Dela

HANGZHOU, China, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Alipay, the world's largest online and mobile payment platform operated by Ant Financial Services Group ("Ant Financial", "Ant"), is now available for Mainland Chinese tourists at all 242 Starbucks branches across Malaysia. Chinese tourists can find a nearest Starbucks through the in-app Discovery platform, and pay for their drinks in RMB via Alipay. Alipay and Starbucks Malaysia are also launching a marketing campaign to celebrate the partnership together with Chinese consumers.

Starting from August 18 to October 31, a Chinese tourist using Alipay in Starbucks can enjoy 10% off with cap at RMB 5 yuan and free drink size upgrade at the same time once every week. The customer will also receive a 10%-off e-voucher for future use upon completion of the first transaction. Alipay and Starbucks Malaysia fund the campaign jointly.

"Starbucks is one of the most visited merchants by Chinese tourists in many countries. Through Alipay's Discovery platform, we are leading our users to the nearest Starbucks wherever they are in Malaysia. Getting a cup of familiar coffee with a familiar payment method at a random street corner in Malaysia, will make one's journey as relaxed as at home," said Dayong Zhang, General Manager of Alipay Southeast Asia.

"Now you can use Alipay to pay for your favorite Starbucks beverage at all Starbucks store around Malaysia, including 32 Drive-Thru concept stores and 15 stores in the airport. It is so convenient that customers just have to flash their mobile application at the counter without going through money exchanger to get a cup of coffee. We would like to invite all Alipay users to enjoy their favorite cup of Starbucks beverage during their stay in Malaysia," said Sydney Quays, Chief Executive Officer of Berjaya Food Berhad.

Merchants in Malaysia started to accept Alipay in April 2017 and it's now available in over 5,000 merchants, including over 2,100 7-Eleven stores. Types of merchants include restaurants, bars, supermarkets, department stores, and convenience stores.

Mainland China is the third largest international visitor market for Malaysia. Over 2.12 million Chinese tourists visited Malaysia in 2016 and a year-on-year increase of 8.3% was seen from the first quarter of 2017.

About Alipay 
Operated by Ant Financial Services Group, Alipay is the world's largest mobile and online payment platform. Launched in 2004, Alipay currently has over 520 million active users and over 450 financial institution partners globally. Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Over 10 million brick-and-mortar merchants now accept Alipay across China. Alipay's in-store payment service is covering more than 30 countries across the world, and tax reimbursement via Alipay is supported in 24 countries and regions. Alipay works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites. Alipay currently supports 19 currencies.

About Starbucks Malaysia 
Berjaya Starbucks Coffee Company Sdn Bhd is wholly owned by Berjaya Group Berhad and a licensee of Starbucks Coffee International. The company operates Starbucks retail locations throughout Malaysia and is committed to offering the world's finest coffee while enriching Malaysians' lives one cup at a time. Starbucks Malaysia has been named as Malaysia's best employer at the Aon Hewitt Best Employers- Malaysia 2015 Awards, receiving the title - 'Best of the Best'. Aon Hewitt Best Employers Award is deemed to be one of the most prestigious awards in recognizing companies with high employee engagement, compelling employer brand, effective leadership and high performance culture. In 2014, Starbucks Malaysia has been awarded with the HR Best Practices Gold Award in the Malaysia Human Resources Award 2014 - organized by the Malaysia Institute of Human Resources Management (MIHRM). For more information, please visit the official site at www.starbucks.com.my or check out our Facebook page at www.facebook.com/StarbucksMalaysia and through the Starbucks Newsroom.

Media Enquiries
Xinyun Yang
International Communications
Ant Financial Services Group
Tel: +86 1381 6896 301
Email: xinyun.yang@antfin.com

Salleharon Ahmad
Public Affairs and Digital Strategy
Starbucks Malaysia
Tel: +6 018-2339166
Email: salleharon@starbucks.com.my



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Alipay (UK) Limited via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum